Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
1.460
+0.070 (5.04%)
Apr 8, 2026, 4:00 PM EDT - Market closed
Marker Therapeutics Revenue
In the year 2025, Marker Therapeutics had annual revenue of $3.55M, down -46.19%. Marker Therapeutics had revenue of $1.10M in the quarter ending December 31, 2025, a decrease of -51.00%.
Revenue (ttm)
$3.55M
Revenue Growth
-46.19%
P/S Ratio
6.86
Revenue / Employee
$709,334
Employees
5
Market Cap
24.34M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.55M | -3.04M | -46.19% |
| Dec 31, 2024 | 6.59M | 3.28M | 99.06% |
| Dec 31, 2023 | 3.31M | -5.70M | -63.26% |
| Dec 31, 2022 | 9.01M | 7.77M | 625.90% |
| Dec 31, 2021 | 1.24M | 774.93K | 166.01% |
| Dec 31, 2020 | 466.79K | 253.59K | 118.95% |
| Dec 31, 2019 | 213.19K | 7.20K | 3.50% |
| Dec 31, 2018 | 205.99K | 22.93K | 12.53% |
| Dec 31, 2017 | 183.06K | -48.14K | -20.82% |
| Dec 31, 2016 | 231.20K | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Neuphoria Therapeutics | 14.99M |
| Barinthus Biotherapeutics | 14.97M |
| Curis | 9.44M |
| Vistagen Therapeutics | 789.00K |
| Lexaria Bioscience | 522.00K |
| Exicure | 500.00K |
| Outlook Therapeutics | 205.70K |
MRKR News
- 21 days ago - Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results - GlobeNewsWire
- 7 weeks ago - Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 3 months ago - Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer - GlobeNewsWire
- 5 months ago - Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 5 months ago - Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors - GlobeNewsWire
- 5 months ago - Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting - GlobeNewsWire
- 6 months ago - Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program - GlobeNewsWire
- 7 months ago - Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire